Quarterly Report and Shareholder Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
- Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
- Amplia and Garvan Institute Enter Collaboration Agreement
- Amplia Completes Single Dose Study of AMP945
- Amplia Initiates Multiple Dose Study of AMP945
Later from Amplia Therapeutics
- Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
- Amplia Announces $3.8m Share Placement
- Proposed issue of Securities - ATX
- App 4E - Preliminary Final Report YE 31 March 2021
- AMP945 Improves Survival in Pacnreatic Cancer Model
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics